Bicyclic Pyridine Derivatives for Selective TAAR1 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropsychiatric disorders, such as schizophrenia and depression, lack effective compounds that target the trace amine-associated receptor TAAR1, which is implicated in regulating monoamine functions and has shown potential in improving cognitive function and treating psychiatric diseases.
Innovation Solution
Development of novel bicyclic pyridine derivatives with agonist activity on the TAAR1 receptor, providing therapeutic agents for neuropsychiatric disorders, which are highly selective for the TAAR1 receptor and have minimal inhibitory effects on other GPCRs like dopamine D2 and adrenergic receptors, ensuring safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neuropsychiatric disorders are used, then existing therapeutic options are available, but they lack effective compounds that target the TAAR1 receptor
Solution Approach 1:
The patent applies parameter changes by modifying molecular structure parameters to create compounds with specific TAAR1 receptor affinity. The bicyclic pyridine derivative structure with specific substituent patterns (R1, R2a-R2d, R3a-R3c, R5a-R5b) represents systematic parameter optimization to achieve selective TAAR1 agonism while maintaining therapeutic efficacy for neuropsychiatric disorders.
2Adaptability or versatility
If compounds with broad GPCR activity are developed, then multiple receptor targets are covered, but selectivity for TAAR1 decreases leading to side effects on other receptors
Solution Approach 1:
The patent applies local quality by designing specific local structural features in the bicyclic pyridine derivative that interact selectively with TAAR1 receptor binding sites. The specific arrangement of substituents at positions R2a-R2d and R3a-R3c creates localized molecular characteristics that match TAAR1's binding pocket geometry and chemical environment, enabling selective interaction without activating other GPCR subtypes.
3Reliability
If novel bicyclic pyridine derivatives are developed for TAAR1 selectivity, then receptor selectivity is improved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex bicyclic pyridine derivative into distinct functional segments: the core bicyclic pyridine scaffold providing TAAR1 binding capability, and various substituent groups (R1, R2a-R2d, R3a-R3c, R5a-R5b) that fine-tune selectivity and pharmacokinetic properties. This modular segmentation allows systematic optimization of selectivity while managing structural complexity through combinatorial substitution patterns.
Data Source
AI summary
The present disclosure provides bicyclic pyridine derivatives.A compound represented by formula I:or a pharmaceutically acceptable salt thereof,whereinX is a oxygen atom, sulfur atom, NR, or CR′R″, n is 0 or 1, R1, R2a, R2b, R2c, R2d, R, R′ and R″ are each independently a hydrogen atom, a halogen atom, optionally substituted C1-6 alkyl, or an optionally substituted C6-10 aryl, or two of R2a, R2b, R2c, R2d, R, R′, and R″, together with a carbon atom or a nitrogen atom to which they are attached, form a 3- to 6-membered saturated carbocyclic ring or saturated heterocyclic ring, and R3a, R3b, R3c and R5a and R5b, are as defined in the description.